<p>在昨天發佈的一份報告中，摩根士丹利的 David Bailey 對 Resmed Inc CHESS 存託憑證維持了買入評級，比例為每普通股 10 個 CDI。該公司的股票今天收盤價為 28.78 澳元。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以便做出更聰明、更精準的決策</li>
<li>發現表現優異的股票投資理念，並升級到市場領先者的投資組合，使用智能投資者精選</li>
</ul>
<p>根據 TipRanks 的數據，Bailey 是一位 4 星分析師，平均回報率為 10.0%，成功率為 45.92%。Bailey 覆蓋醫療保健行業，專注於 Ramsay Health Care、Telix Pharmaceuticals 和 Cochlear 等股票。</p>
<p>Resmed Inc CHESS 存託憑證的分析師共識為強烈買入，目標價格共識為 43.13 澳元，相較於當前水平有 49.86% 的上漲空間。在 5 月 4 日發佈的一份報告中，Morgans 也對該股票維持了買入評級，目標價格為 41.72 澳元。</p>

瑞思邁

<p>摩根士丹利分析師大衞·貝利對瑞思邁（Resmed Inc）CHESS 存託憑證維持 “買入” 評級，收盤價為 28.78 澳元。分析師共識為 “強烈買入”，目標價為 43.13 澳元，意味着潛在上漲幅度為 49.86%。貝利是一位四星級分析師，之前在 5 月份的報告中設定的目標價為 41.72 澳元。他覆蓋醫療保健行業，關注的公司包括拉姆齊醫療（Ramsay Health Care）和泰利克斯製藥（Telix Pharmaceuticals）</p>

<p>In a report released yesterday, David Bailey from Morgan Stanley maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh. The company’s shares closed today at A$28.78.</p>
<div class="lb-trans"><p>在昨天發佈的一份報告中，摩根士丹利的 David Bailey 對 Resmed Inc CHESS 存託憑證維持了買入評級，比例為每普通股 10 個 CDI。該公司的股票今天收盤價為 28.78 澳元。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以便做出更聰明、更精準的決策</li>
<li>發現表現優異的股票投資理念，並升級到市場領先者的投資組合，使用智能投資者精選</li>
</ul>
</div><p>According to TipRanks, Bailey is a 4-star analyst with an average return of 10.0% and a 45.92% success rate. Bailey covers the Healthcare sector, focusing on stocks such as Ramsay Health Care, Telix Pharmaceuticals, and Cochlear .</p>
<div class="lb-trans"><p>根據 TipRanks 的數據，Bailey 是一位 4 星分析師，平均回報率為 10.0%，成功率為 45.92%。Bailey 覆蓋醫療保健行業，專注於 Ramsay Health Care、Telix Pharmaceuticals 和 Cochlear 等股票。</p>
</div><p>Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh has an analyst consensus of Strong Buy, with a price target consensus of A$43.13, which is a 49.86% upside from current levels. In a report released on May 4, Morgans also maintained a Buy rating on the stock with a A$41.72 price target.</p>
<div class="lb-trans"><p>Resmed Inc CHESS 存託憑證的分析師共識為強烈買入，目標價格共識為 43.13 澳元，相較於當前水平有 49.86% 的上漲空間。在 5 月 4 日發佈的一份報告中，Morgans 也對該股票維持了買入評級，目標價格為 41.72 澳元。</p>
</div>

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Receives a Buy from Morgan Stanley

Tip Ranks

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

摩根士丹利

Ramsay Health Care Limited

Telix Pharmaceuticals Ltd.

Telix Pharmaceuticals

Cochlear Limited

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

瑞思邁公司 CHESS 存託權益以每 10 個 CDI 對應一股普通股的比例（RMD）獲得摩根士丹利的買入評級